Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro

PLoS ONE

Volumn 13, Issue 5, 2018, Pages

  Speer, Esther M ^a   Dowling, David J ^b,c   Xu, Jianjin ^d   Ozog, Lukasz S ^a   Mathew, Jaime A ^a   Chander, Avinash ^a   Yin, Donglei ^d   Levy, Ofer ^b,c  

^a STONY BROOK UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Stony Brook University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZITHROMYCIN; DEXAMETHASONE; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PENTOXIFYLLINE; PHOSPHODIESTERASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; CYTOKINE; DUSP1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1;

ADULT; AGE DISTRIBUTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENZYME ASSAY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MONOTHERAPY; NEWBORN; REAL TIME POLYMERASE CHAIN REACTION; STIMULATION; SUPERNATANT; ADOLESCENT; AGING; BIOSYNTHESIS; BLOOD; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONOCYTE; PREGNANCY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGING; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; CASPASE 1; CYTOKINES; DEXAMETHASONE; DRUG SYNERGISM; DUAL SPECIFICITY PHOSPHATASE 1; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFANT, NEWBORN; INFLAMMASOMES; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; NF-KAPPA B; PENTOXIFYLLINE; PREGNANCY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 85046364989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0196352     Document Type: Article

References (76)

1. Kuban KC, O’Shea TM, Allred EN, Paneth N, Hirtz D, Fichorova RN, et al. Systemic inflammation and cerebral palsy risk in extremely preterm infants. J Child Neurol. 2014; 29: 1692–1698. https://doi.org/10.1177/0883073813513335 PMID: 24646503
2. Cornette L. Fetal and neonatal inflammatory response and adverse outcome. Semin Fetal Neonatal Med. 2004; 9: 459–470. https://doi.org/10.1016/j.siny.2004.08.004 PMID: 15691784
3. Hagberg H, Wennerholm UB, Savman K. Sequelae of chorioamnionitis. Curr Opin Infect Dis. 2002; 15: 301–306. PMID: 12015466
4. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; CD001146. https://doi.org/10.1002/14651858.CD001146.pub5 PMID: 29063585
5. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; CD001145. https://doi.org/10.1002/14651858.CD001145.pub4 PMID: 29063594
6. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008; 39: 127–132. https://doi.org/10.1165/rcmb.2008-0091TR PMID: 18323530
7. Schulzke SM, Kaempfen S, Patole SK. Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2014; CD010018. https://doi.org/10.1002/14651858.CD010018.pub2 PMID: 25418278
8. Harris E, Schulzke SM, Patole SK. Pentoxifylline in preterm neonates: a systematic review. Pediatr Drugs. 2010; 12: 301–311.
9. Turhan AH, Atıcı A, Muşlu N, Polat A, Helvacı İ. The effects of pentoxifylline on lung inflammation in a rat model of meconium aspiration syndrome. Exp Lung Res. 2012; 38: 250–255. https://doi.org/10.3109/01902148.2012.676704 PMID: 22489651
10. Kalay S, Oztekin O, Tezel G, Aldemir H, Sahin E, Koksoy S, et al. The effects of intraperitoneal pentoxifylline treatment in rat pups with hypoxic-ischemic encephalopathy. Pediatr Neurol. 2013; 49: 319–323. https://doi.org/10.1016/j.pediatrneurol.2013.05.011 PMID: 23993832
11. Travadi J, Patole S, Charles A, Dvorak B, Doherty D, Simmer K. Pentoxifylline reduces the incidence and severity of necrotizing enterocolitis in a neonatal rat model. Pediatr Res. 2006; 60: 185–189. https://doi.org/10.1203/01.pdr.0000228325.24945.ac PMID: 16864701
12. Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. 2015; CD004205. https://doi.org/10.1002/14651858.CD004205.pub3PMID: 25751631
13. Shabaan AE, Nasef N, Shouman B, Nour I, Mesbah A, Abdel-Hady H. Pentoxifylline therapy for late-onset sepsis in preterm infants: a randomized controlled trial. Pediatr Infect Dis J. 2015; 34: e143–e148. https://doi.org/10.1097/INF.0000000000000698 PMID: 25970116
14. Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007; 62: 483–488. https://doi.org/10.1203/PDR.0b013e318142582dPMID: 17667842
15. Vrančić M, Banjanac M, Nujić K, Bosnar M, Murati T, Munić V, et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol. 2012; 165: 1348–1360. https://doi.org/10.1111/j.1476-5381.2011.01576.x PMID: 21726210
16. Bosnar M, Dominis-Kramarić M, Nujić K, Stupin Polančec D, Marjanović N, Glojnarić I, et al. Immuno-modulatory effects of azithromycin on the establishment of lipopolysaccharide tolerance in mice. Int Immunopharmacol. 2013; 15: 498–504. https://doi.org/10.1016/j.intimp.2013.02.011 PMID: 23462295
17. Simone JV. Childhood leukemia as a model for cancer research: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1979; 39: 4301–4307. PMID: 291475
18. Johnson SC. Antiretroviral therapy for HIV infection: when to initiate therapy, which regimen to use, and how to monitor patients on therapy. Top Antivir Med. 2016; 23: 161–167. PMID: 27398769
19. Philbin VJ, Dowling DJ, Gallington LC, Cortés G, Tan Z, Suter EE, et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol. 2012; 130: 195–204. https://doi.org/10.1016/j.jaci.2012.02.042 PMID: 22521247
20. Speer EM, Dowling DJ, Ozog LS, Xu J, Yang J, Kennady G, et al. Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns. Pediatr Res. 2017; 81: 806–816. https://doi.org/10.1038/pr.2017.6 PMID: 28072760
21. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-α production in the human newborn. J Immunol. 2006; 177: 1956–1966. PMID: 16849509
22. Belberdos ME, Levy O, Meyaard L, Bont L. Plasma-mediated immune suppression: a neonatal perspective. Pediatr Allergy Immunol. 2013; 24: 102–113. https://doi.org/10.1111/pai.12023 PMID: 23173652
23. Elahi S, Ertelt JM, Kinder JM, Jiang TT, Zhang X, Xin L, et al. Immunosuppressive CD71+ erythroid cells compromise neonatal host defense against infection. Nature. 2013; 504: 158–162. https://doi.org/10.1038/nature12675 PMID: 24196717
24. Szymura-Oleksiak J, Bury J, Lauterbach R, Pawlowski M. Serum concentrations of pentoxifylline and its metabolites in premature infants with sepsis when administered by continuous intravenous infusion. Pharmaceutical Sciences. 1997; 3: 367–371.
25. Page-Sharp M, Strunk T, Salman S, Hibbert J, Patole SK, Manning L, et al. Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. J Pharm Biomed Anal. 2017; 146: 302–313. https://doi.org/10.1016/j.jpba.2017.08.030 PMID: 28903089
26. Lugo RA, Nahata MC, Menke JA, McClead RE Jr. Pharmacokinetics of dexamethasone in premature infants. Eur J Clin Pharmacol. 1996; 49: 477–483. PMID: 8706773
27. Merchan LM, Hassan HE, Terrin ML, Waites KB, Kaufman DA, Ambalavanan N, et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. Antimicrob Agents Chemother. 2015; 59: 570–578. https://doi.org/10.1128/AAC.03951-14 PMID: 25385115
28. Pestana EA, Belak S, Diallo A, Crowther JR, Viljoen GJ. Early, rapid and sensitive veterinary molecular diagnostics—real time PCR applications. Dordrecht, Netherlands: Springer Science & Business Media; 2010. p. 247–263.
29. Berenbaum MC. What is synergy? Pharmacol Rev. 1989; 41: 93–141. PMID: 2692037
30. Harbron C. A flexible unified approach to the analysis of pre-clinical combination studies. Statist Med. 2010; 29: 1746–1756.
31. Bender R, Lange S. Adjusting for multiple testing—when and how? J Clin Epidemiol. 2001; 54: 343–349. PMID: 11297884
32. ® 14.2 User’s Guide. Cary, NC: SAS Institute Inc.; 2016.
33. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity. 2012; 37: 771–783. https://doi.org/10.1016/j.immuni.2012.10.014 PMID: 23159225
34. Pettengill MA, van Haren SD, Levy O. Soluble mediators regulating immunity in early life. Front Immunol. 2014; 5: 457. https://doi.org/10.3389/fimmu.2014.00457 PMID: 25309541
35. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One. 2010; 5: e15041. https://doi.org/10.1371/journal.pone.0015041 PMID: 21152080
36. Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One. 2011; 6: e18185. https://doi.org/10.1371/journal.pone.0018185 PMID: 21533209
37. Redondo AC, Ceccon ME, Silveira-Lessa AL, Quinello C, Palmeira P, Carvalho WB, et al. TLR-2 and TLR-4 expression in monocytes of newborns with late-onset sepsis. J Pediatr (Rio J). 2014; 90: 472–478.
38. Bi D, Qiao L, Bergelson I, Ek CJ, Duan L, Zhang X, et al. Staphylococcus epidermidis bacteremia induces brain injury in neonatal mice via Toll-like receptor 2-dependent and -independent pathways. J Infect Dis. 2015; 212: 1480–1490. https://doi.org/10.1093/infdis/jiv231 PMID: 25883383
39. Mallard C, Wang X, Hagberg H. The role of Toll-like receptors in perinatal brain injury. Clin Perinatol. 2009; 36: 763–772. https://doi.org/10.1016/j.clp.2009.07.009 PMID: 19944834
40. Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis. 2014; 14: 751–762. https://doi.org/10.1016/S1473-3099(14) 70710-8 PMID: 24877996
41. Battersby AJ, Khara J, Wright VJ, Levy O, Kampmann B. Antimicrobial proteins and peptides in early life: ontogeny and translational opportunities. Front Immunol. 2016; 7: 309. https://doi.org/10.3389/fimmu.2016.00309 PMID: 27588020
42. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/ tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990; 172: 391–394. PMID: 2358784
43. Funk JO, Ernst M, Schönharting MM, Zabel P. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporine A. Int J lmmunopharmacol. 1995; 17: 1007–1016.
44. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G, et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunology. 1997; 91: 197–203. PMID: 9227317
45. Sittel C, Sittel A, Guntinas-Lichius O, Eckel HE, Stennert E. Bell’s palsy: a 10-year experience with anti-phlogistic-rheologic infusion therapy. Am J Otol. 2000; 21: 425–432. PMID: 10821559
46. Michel O, Jahns T, Joost-Enneking M, Neugebauer P, Streppel M, Stennert E. [The Stennert antiphlo-gistic-rheologic infusion schema in treatment of cochleovestibular disorders]. HNO. 2000; 48: 182–188. German. PMID: 10768108
47. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. 2007; 7: 379–390. https://doi.org/10.1038/nri2075 PMID: 17457344
48. Angelone DF, Wessels MR, Coughlin M, Suter EE, Valentini P, Kalish LA, et al. Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-α production in vitro and in vivo. Pediatr Res. 2006; 60: 205–209. https://doi.org/10.1203/01.pdr.0000228319.10481.ea PMID: 16864705
49. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005; 175: 3463–3468. PMID: 16148087
50. Broering R, Montag M, Jiang M, Lu M, Sowa JP, Kleinehr K, et al. Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state. Int Immunol. 2011; 23: 537–544. https://doi.org/10.1093/intimm/dxr048 PMID: 21750146
51. Van Furth AM, Seijmonsbergen EM, Langermans JA, van der Meide PH, van Furth R. Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1 beta (IL-1 beta), and IL-10 by human leukocytes. Clin Diagn Lab Immunol. 1995; 2: 689–692. PMID: 8574830
52. Xie X, Yan X, Lin Z, Jin X. Differential effects of low- and high-dose glucocorticoids on the innate immunity of corneal epithelium in vitro. Ocul Immunol Inflamm. 2011; 19: 275–281. https://doi.org/10.3109/09273948.2011.569110 PMID: 21770806
53. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, et al. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of Toll-like receptor 2. J Biol Chem. 2002; 277: 47444–47450. https://doi.org/10.1074/jbc.M208140200 PMID: 12356755
54. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002; 218: 74–86. PMID: 12470615
55. Philbin VJ, Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leuco-cytes: basic mechanisms and translational opportunities. Biochem Soc Trans. 2007; 35: 1485–1491. https://doi.org/10.1042/BST0351485 PMID: 18031250
56. Schüller SS, Wisgrill L, Herndl E, Spittler A, Förster-Waldl E, Sadeghi K, et al. Pentoxifylline modulates LPS-induced hyperinflammation in monocytes of preterm infants in vitro. Pediatr Res. 2017; 82: 215–225. https://doi.org/10.1038/pr.2017.41 PMID: 28288151
57. Trial of intravenous azithromycin to eradicate Ureaplasma respiratory tract infection in preterm infants (AZIPIII), NCT 01778634, https://clinicaltrials.gov/ct2/show/NCT01778634, last updated on June 26, 2017.
58. Grimaldi D, Llitjos JF, Pène F. Post-infectious immune suppression: a new paradigm of severe infections. Med Mal Infect. 2014; 44: 455–463. https://doi.org/10.1016/j.medmal.2014.07.017 PMID: 25169939
59. Cavaillon JM, Eisen D, Annane D. Is boosting the immune system in sepsis appropriate? Crit Care. 2014; 18: 216. https://doi.org/10.1186/cc13787 PMID: 24886820
60. Tarnow-Mordi W, Isaacs D, Dutta S. Adjunctive immunologic interventions in neonatal sepsis. Clin Perinatol. 2010; 37: 481–499. https://doi.org/10.1016/j.clp.2009.12.002 PMID: 20569818
61. Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep. 2015; 5:12016. https://doi.org/10.1038/srep12016 PMID: 26152605
62. Fan LC, Lin JL, Yang JW, Mao B, Lu HW, Ge BX, et al. Macrolides protect against Pseudomonas aeru-ginosa infection via inhibition of inflammasomes. Am J Physiol Lung Cell Mol Physiol. 2017; 313: L677–L686. https://doi.org/10.1152/ajplung.00123.2017 PMID: 28684545
63. Van Furth AM, Steenwijk TM, Langermans JA, van Furth R. In vitro effect of dexamethasone, pentoxifylline, and anti-endotoxin monoclonal antibody on the release of proinflammatory mediators by human leukocytes stimulated with Haemophilus influenzae type B. Pediatr Res. 1994; 35: 725–728. https://doi.org/10.1203/00006450-199406000-00020 PMID: 7936825
64. Chan B, Kalabalikis P, Klein N, Heyderman R, Levin M. Assessment of the effect of candidate anti-inflammatory treatments on the interaction between meningococci and inflammatory cells in vitro in a whole blood model. Biotherapy. 1996; 9: 221–228. PMID: 9012541
65. Van Haren SD, Dowling DJ, Foppen W, Christensen D, Andersen P, Reed SG, et al. Age-specific adjuvant synergy: dual TLR7/8 and mincle activation of human newborn dendritic cells enables Th1 polarization. J Immunol. 2016; 197: 4413–4424. https://doi.org/10.4049/jimmunol.1600282 PMID: 27793997
66. Lim G, Lee BS, Choi YS, Park HW, Chung ML, Choi HJ, et al. Delayed dexamethasone therapy and neurodevelopmental outcomes in preterm infants with bronchopulmonary dysplasia. Pediatr Neonatol. 2015; 56: 261–267. https://doi.org/10.1016/j.pedneo.2014.11.006 PMID: 25649722
67. Halliday HL. Update on postnatal steroids. Neonatology. 2017; 111: 415–422. https://doi.org/10.1159/ 000458460 PMID: 28538237
68. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al.; PREMILOC trial study group. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016; 387: 1827–1836. https://doi.org/10.1016/S0140-6736(16)00202-6 PMID: 26916176
69. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C; PREMILOC Trial Group. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA. 2017; 317: 1329–1337. https://doi.org/10.1001/jama.2017.2692PMID: 28384828
70. Du Pont-Thibodeau G, Joyal JS, Lacroix J. Management of neonatal sepsis in term newborns. F1000Prime Rep. 2014; 6: 67. https://doi.org/10.12703/P6-67 PMID: 25165566
71. Rettig L, Haen SP, Bittermann AG, von Boehmer L, Curioni A, Krämer SD, et al. Particle size and activation threshold: a new dimension of danger signaling. Blood. 2010; 115: 4533–4541. https://doi.org/10.1182/blood-2009-11-247817 PMID: 20304804
72. Strunk T, Power Coombs MR, Currie AJ, Richmond P, Golenbock DT, Stoler-Barak L, et al. TLR2 mediates recognition of live Staphylococcus epidermidis and clearance of bacteremia. PLoS One. 2010; 5: e10111. https://doi.org/10.1371/journal.pone.0010111 PMID: 20404927
73. Dowling DJ, van Haren SD, Scheid A, Bergelson I, Kim D, Mancuso CJ, et al. TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. JCI Insight. 2017; 2: e91020. https://doi.org/10.1172/jci.insight.91020 PMID: 28352660
74. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol. 2014; 35: 299–310. https://doi.org/10.1016/j.it.2014.04.007 PMID: 24880460
75. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes with age. Nat Rev Immunol. 2004; 4: 553–564. https://doi.org/10.1038/nri1394 PMID: 15229474
76. Can pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomized, placebo-controlled trial. Australian New Zealand Clinical Trials Registry ACTRN12616000405415, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id= 370404, last updated on August 3, 2017.